English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine BioTech
维梧苏州基金及晟德大药厂认购东曜药业股份
Jun 01, 2022 12:10 HKT
維梧蘇州基金及晟德大藥廠認購東曜藥業股份
Jun 01, 2022 12:09 HKT
Connected Transactions Involving Subscription by Vivo Suzhou Fund and Centerlab for TOT BIOPHARM Shares
Jun 01, 2022 12:08 HKT
Sirnaomics启动RNAi治疗药物STP705进行用于医学美容治疗的成人腹部减脂整形I期临床研究
May 30, 2022 15:40 HKT
Sirnaomics啟動RNAi治療藥物STP705進行用於醫學美容治療的成人腹部減脂整形I期臨床研究
May 30, 2022 15:39 HKT
Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment
May 30, 2022 15:38 HKT
The APCO Bone Health QI Tool Kit - Putting a brake on fractures in the world's most populous & fastest ageing region
May 24, 2022 08:21 HKT
The APCO Bone Health QI Tool Kit - Putting a brake on fractures in the world's most populous & fastest ageing region
May 24, 2022 08:01 HKT
The APCO Bone Health QI Tool Kit - Putting a brake on fractures in the world's most populous & fastest ageing region
May 24, 2022 07:40 HKT
The APCO Bone Health QI Tool Kit - Putting a brake on fractures in the world's fastest ageing region
May 24, 2022 06:00 HKT
Malaysian Genomics Resource Centre Berhad Posts 212% Increase in Revenue for 3Q FY2022
May 23, 2022 21:00 HKT
医思健康收购连锁体检中心 进一步扩大客户基础整合健康检查市场
May 23, 2022 19:53 HKT
醫思健康收購連鎖體檢中心 進一步擴大客戶基礎整合健康檢查市場
May 23, 2022 19:52 HKT
EC Healthcare Acquires Health Screening Services Chain, Further Expand Customer Base and Consolidate the Health Screening Market
May 23, 2022 19:51 HKT
沛嘉医疗Tethys AS抽吸导管及Fastunnel输送型球囊扩张导管获NMPA批准上市
May 23, 2022 17:46 HKT
沛嘉醫療Tethys AS抽吸導管及Fastunnel輸送型球囊擴張導管獲NMPA批准上市
May 23, 2022 17:45 HKT
金活醫藥即將銷售新冠抗原試劑盒!
May 20, 2022 16:30 HKT
金活醫藥即將銷售新冠抗原試劑盒!
May 20, 2022 14:09 HKT
Sirnaomics将在2022年Pre-ASCO中国峰会介绍其RNAi疗法于肿瘤学领域临床研究结果与发展战略
May 20, 2022 11:12 HKT
Sirnaomics將在2022年Pre-ASCO中國峰會介紹其RNAi療法於腫瘤學領域臨床研究結果與發展戰略
May 20, 2022 11:11 HKT
<< Previous  Next >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: